|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/23/22 Biocept Inc. 10-Q 3/31/22 69:8.2M ActiveDisclosure/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 940K
2: EX-10.1 Material Contract HTML 262K
3: EX-31.1 Certification -- §302 - SOA'02 HTML 28K
4: EX-31.2 Certification -- §302 - SOA'02 HTML 28K
5: EX-32.1 Certification -- §906 - SOA'02 HTML 22K
6: EX-32.2 Certification -- §906 - SOA'02 HTML 23K
12: R1 Document and Entity Information HTML 74K
13: R2 Condensed Balance Sheets HTML 114K
14: R3 Condensed Balance Sheets (Parenthetical) HTML 39K
15: R4 Condensed Statements of Operations and HTML 96K
Comprehensive Loss (Unaudited)
16: R5 Condensed Statements of Shareholders' Equity HTML 61K
17: R6 Condensed Statements of Cash Flows (Unaudited) HTML 90K
18: R7 Condensed Statements of Cash Flows (Unaudited) HTML 26K
(Parenthetical)
19: R8 The Company, Business Activities and Basis of HTML 121K
Presentation
20: R9 Liquidity HTML 27K
21: R10 Sales of Equity Securities HTML 29K
22: R11 Fair Value Measurement HTML 35K
23: R12 Balance Sheet Details HTML 104K
24: R13 Leases HTML 177K
25: R14 Stock-Based Compensation HTML 95K
26: R15 Common Stock Warrants Outstanding HTML 66K
27: R16 Net Loss per Common Share HTML 46K
28: R17 Commitments and Contingencies HTML 25K
29: R18 Related Party Transactions HTML 25K
30: R19 Subsequent Events HTML 23K
31: R20 The Company, Business Activities and Basis of HTML 127K
Presentation (Policies)
32: R21 The Company, Business Activities and Basis of HTML 94K
Presentation (Tables)
33: R22 Fair Value Measurement (Tables) HTML 29K
34: R23 Balance Sheet Details (Tables) HTML 103K
35: R24 Leases (Tables) HTML 177K
36: R25 Stock-Based Compensation (Tables) HTML 96K
37: R26 Common Stock Warrants Outstanding (Tables) HTML 63K
38: R27 Net Loss per Common Share (Tables) HTML 45K
39: R28 The Company, Business Activities and Basis of HTML 46K
Presentation - Additional Information (Detail)
40: R29 The Company, Business Activities and Basis of HTML 39K
Presentation - Composition of Net Revenues
Recognized Disaggregated by Source (Detail)
41: R30 The Company, Business Activities and Basis of HTML 34K
Presentation - Composition of Net Revenues
Recognized Disaggregated by Nature (Detail)
42: R31 The Company, Business Activities and Basis of HTML 39K
Presentation - Summary of Third-Party Payers That
Represent More Than 10% of Total Net Revenues and
Total Net Accounts Receivable and Their Related
Percentage (Detail)
43: R32 Liquidity - Additional Information (Detail) HTML 53K
44: R33 Sales of Equity Securities - Additional HTML 66K
Information (Detail)
45: R34 Fair Value Measurement - Additional Information HTML 53K
(Detail)
46: R35 Fair Value Measurement - Assumptions Used for HTML 38K
Determining Fair Values of Common Stock Warrants
(Detail)
47: R36 Balance Sheet Details - Schedule of Fixed Assets HTML 68K
and Accrued Liabilities (Detail)
48: R37 Leases - Additional Information (Detail) HTML 122K
49: R38 Leases - Schedule of Right-Of-Use Lease Assets HTML 26K
(Detail)
50: R39 Leases - Schedule of Current Portion of Operating HTML 27K
and Finance Lease Liabilities (Detail)
51: R40 Leases - Schedule of Long-Term Portion of HTML 27K
Operating and Finance Lease Liabilities (Detail)
52: R41 Leases - Schedule of Lease Expense (Detail) HTML 30K
53: R42 Leases - Schedule of Remaining Future Minimum HTML 71K
Lease Payments for Finance and Operating Leases
(Detail)
54: R43 Leases - Supplemental Cash Flow Information HTML 28K
Related to Operating and Finance Leases (Detail)
55: R44 Stock-Based Compensation - Additional Information HTML 73K
(Detail)
56: R45 Stock-Based Compensation - Summary of Stock Option HTML 46K
Activity (Detail)
57: R46 Stock-Based Compensation - Assumptions Used for HTML 40K
Determining Fair Value of Stock Options Under
Black-Scholes Pricing Model (Detail)
58: R47 Stock-Based Compensation - Effects of Stock-Based HTML 34K
Compensation Related to Equity Awards to Employees
and Nonemployees on Condensed Statement of
Operations and Comprehensive Loss (Detail)
59: R48 Common Stock Warrants Outstanding - Summary of HTML 28K
Equity-Classified Common Stock Warrant Activity
(Detail)
60: R49 Common Stock Warrants Outstanding - Additional HTML 40K
Information (Detail)
61: R50 Net Loss per Common Share - Additional Information HTML 27K
(Detail)
62: R51 Net Loss per Common Share - Schedule of HTML 34K
Anti-Dilutive Securities Excluded from
Computations of Diluted Weighted-Average Shares
(Detail)
63: R52 Commitments and Contingencies - Additional HTML 29K
Information (Detail)
64: R53 Related Party Transactions - Additional HTML 29K
Information (Detail)
67: XML IDEA XML File -- Filing Summary XML 123K
65: XML XBRL Instance -- bioc-10q_20220331_htm XML 1.68M
66: EXCEL IDEA Workbook of Financial Reports XLSX 78K
8: EX-101.CAL XBRL Calculations -- bioc-20220331_cal XML 162K
9: EX-101.DEF XBRL Definitions -- bioc-20220331_def XML 429K
10: EX-101.LAB XBRL Labels -- bioc-20220331_lab XML 1.17M
11: EX-101.PRE XBRL Presentations -- bioc-20220331_pre XML 817K
7: EX-101.SCH XBRL Schema -- bioc-20220331 XSD 188K
68: JSON XBRL Instance as JSON Data -- MetaLinks 342± 517K
69: ZIP XBRL Zipped Folder -- 0001564590-22-020962-xbrl Zip 276K
EXHIBIT 31.1
CERTIFICATION
I, Samuel D. Riccitelli, certify that:
|
1. |
I have reviewed this Quarterly Report on Form 10-Q of Biocept, Inc.; |
|
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
|
4. |
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|
|
a. |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
|
b. |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|
|
c. |
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|
|
d. |
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
|
5. |
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
|
|
a. |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
|
|
b. |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Date: May 23, 2022
|
President and Interim Chief Executive Officer (Principal Executive Officer) |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 5/23/22 | 8-K | ||
| For Period end: | 3/31/22 | 4, 8-K, NT 10-Q | ||
| List all Filings | ||||